Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270082 · ClinicalTrials.gov registry record · Phase 1
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
A Phase 1 study, sponsored by Ikena Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT06270082 is a Phase 1 study that was terminated before completion, run by Ikena Oncology. The registered enrollment target is 75 participants.
The verdict
NCT06270082, a Phase 1 study, was terminated before completion, sponsored by Ikena Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Interventions
- DRUG IK-595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2025-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06270082
The ClinicalTrials.gov registry entry for NCT06270082 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ikena Oncology, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IK-595 is the first listed.
NCT06270082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06270082 about?
NCT06270082 is a clinical study titled "Study of IK-595 in RAS- or RAF-altered Advanced Tumors". This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumo...
What is the current status of trial NCT06270082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-12-18. Estimated completion is 2025-09-08.
What interventions are being tested in trial NCT06270082?
The interventions under investigation include: IK-595 (DRUG).
Who is sponsoring clinical trial NCT06270082?
This trial is sponsored by Ikena Oncology, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.